Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics (NASDAQ:PTGX) announced that it will be eligible to receive $60M in milestone payments in Q4 for the advancement of JNJ-2113 into multiple clinical development programs led by Janssen Biotech, a Johnson & Johnson company. The ICONIC clinical development program in adult patients with moderate to severe psoriasis is advancing to Phase 3 with two studies starting in November, and the ANTHEM-UC Phase 2b study in adults with moderately to severely active ulcerative colitis will begin this month.
October 09, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics is set to receive $60M in milestone payments in Q4 for the advancement of JNJ-2113, which could positively impact its financial performance.
The news of Protagonist Therapeutics receiving $60M in milestone payments for the advancement of JNJ-2113 is directly related to the company's financial performance. This could lead to increased investor confidence and potentially a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100